Beyond Appetite: Fine Dining in the GLP-1 Era

10 Minute read

09 Oct 2026

Credit: Urban Gyllstrom on Unsplash

As weight-loss drugs change the way people eat, restaurants are exploring how to satisfy smaller appetites while preserving the pleasure of dining out.

Restaurant menus have always shifted with the way people eat. Plant-based diets brought more vegetables to the center of the plate; the appetite for sharing turned small plates into a restaurant genre of their own; and the protein boom put grams of protein next to prices. But GLP-1 drugs, used to treat type 2 diabetes and obesity, are proving more complicated.

The restaurant industry’s most visible response has been the arrival of the “GLP-1-friendly” menu. Chipotle began flagging high-protein, high-fiber options for customers taking the drugs. Smoothie King built an entire GLP-1 Support Menu around protein-rich drinks with no added sugar, while Shake Shack began identifying items on its Good Fit Menu as “GLP-1-friendly.” Fine Dining Lovers has reported on restaurants experimenting with smaller portions and dishes designed around reduced appetites.

The idea has also reached fine dining. At Heston Blumenthal’s three-Michelin-starred The Fat Duck in Bray, England, the Mindful Experience offers scaled-back versions of the restaurant’s dishes, built around what Blumenthal calls “fulfilment rather than fullness.”

But as GLP-1 use continues to grow, what might have looked like another menu trend is becoming harder for restaurants to ignore. The drugs are changing how people shop for food, how much they eat, and, increasingly, how they dine out. In the U.S., roughly one in eight adults reported taking a GLP-1 medication in a March 2026 KFF poll. Restaurants are serving customers who still want to go out to eat but may arrive at the table with very different appetites.

When Appetite Changes

According to a National Restaurant Association report published in May 2026, 93% of GLP-1 users surveyed said they had changed how they order at restaurants since starting the medication. Nearly half (49%) said they were choosing smaller portions, while 43% were ordering more high-protein items and 41% more vegetables. Thirty-eight percent reported ordering fewer sugary items, and the same share reported ordering fewer indulgent dishes, including desserts. Among users 21 and older, 28% said they were ordering less alcohol.

Numbers like these put restaurants in a peculiar position. They have always adapted to changing tastes, diets, and economic pressures. But GLP-1 drugs intervene in something more fundamental: appetite itself. The scale of that change is still unclear, but there is a parallel with the sexual revolution, when the birth-control pill helped reshape our relationship with another basic human desire. Decades later, erectile-dysfunction drugs changed that relationship again. GLP-1s do something different: they can suppress the desire to eat.

That distinction matters at the restaurant table. GLP-1 drugs can reduce the motivation to seek out food, the “wanting,” without necessarily eliminating the pleasure of eating it, the “liking.” “These drugs reduce eating as an activity that people look forward to,” says Scott M. Sternson, a professor of neurosciences at the UC San Diego School of Medicine. In a mouse study published in Science, he and his colleagues found that dopamine neurons involved in eating for pleasure could counteract the appetite-suppressing effects of semaglutide, a GLP-1 drug.

Food and flavor may be at the center of the experience, Sternson says, but restaurants also offer social interaction, ritual, and novelty. “Restaurants that provide this added experience will likely be favored by people on GLP-1 drugs,” he says, adding that “there is still a desire to be entertained, so restaurants may need to adapt to this.”

Keeping Diners Engaged

At many fine-dining restaurants, the goal remains much the same: to keep guests engaged and, somehow, hungry for what comes next throughout the tasting menu. “I have the impression that people using these drugs become even more intentional about the meals they choose to have,” says Bernardo Silva, co-founder of Frevo, a Michelin-starred restaurant in New York’s Greenwich Village. Fine dining, Silva argues, is already an intentional meal: people book it for the experience, to celebrate an occasion, or to encounter a different perspective on food.

Even before GLP-1 drugs became widely used, he says, guests would arrive having planned their day around dinner. “I’ve heard customers say, ‘I didn’t have lunch today because I was preparing for this meal.’ They wanted to make the most of the experience.”

Managing appetite was already part of the job. “We’ve always been concerned about making sure the meal isn’t too heavy. It’s a difficult balance because people have different appetites,” he says. Anyone familiar with tasting menus knows the feeling: there are still three or four courses to go, and you’re already full. “It’s not a good feeling,” Silva adds. “For us, that concern existed before GLP-1.”

Part of the answer may lie in making satiety as much a consideration as flavor. The paradox of the tasting menu is that its plates may be small, but the meal itself often isn’t. Spread across ten, fifteen, or more courses, dinner can add up quickly.

But variety can encourage us to keep eating. As we eat the same food, our pleasure in it declines, while foods with different flavors can remain appealing. Scientists call this sensory-specific satiety. Research has found that people eat more when multicourse meals offer greater variety. Just as one flavor loses its pull, another arrives: acidic after fatty, crisp after soft, cold after hot, savory before sweet. “Pleasure and liking are more rapidly reduced by satiety, fullness, and lack of novelty,” Sternson says. GLP-1 drugs can bring that fullness on sooner.

Lighter by Design

At SingleThread, the three-Michelin-starred restaurant in Healdsburg, California, chef Kyle Connaughton says he has not noticed an impact from diners taking the drugs. He describes its ten-course, kaiseki-inspired tasting menu as built around vegetables, seafood, and lean proteins, with relatively little sugar, carbohydrates, or heavy dairy. “Maybe we were a bit ahead of the curve naturally for some of these trends, but hardly in a conscious way,” Connaughton says.

That doesn’t mean, he cautions, that SingleThread’s menu “naturally appeals to a GLP-1 user.” The drugs have never figured into how the restaurant cooks, he says. Instead, its lighter approach comes from the experience it wants to create and happens to align with what a growing number of diners are now seeking. Much of the produce comes from SingleThread’s 24-acre farm, where vegetables are harvested at peak ripeness, and preparations tend to support rather than overwhelm their flavors.

“It’s a natural process for us that comes from the experience we want guests to have,” Connaughton says. “And definitely to avoid the experience we don’t want them to have: feeling too full, feeling ‘hungover’ from too much rich or sweet food. It’s just our own way of liking to cook and dine ourselves.”